Athena Farahzadi, Fatemeh Moosaie, Seyed Mohammad Tavangar, Hojat Ebrahiminik, Sepide Javankiani, Hossein Chegeni, Mohammad Shirkhoda
{"title":"Surgical versus non-surgical management of hyperfunctional thyroid metastasis: a case report.","authors":"Athena Farahzadi, Fatemeh Moosaie, Seyed Mohammad Tavangar, Hojat Ebrahiminik, Sepide Javankiani, Hossein Chegeni, Mohammad Shirkhoda","doi":"10.1186/s13256-024-04820-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperthyroidism, caused by metastatic differentiated thyroid cancer, is a rare condition that can be difficult to diagnose. Thyrotoxicosis and metastatic disease regarding functional metastasis increase morbidity and mortality in patients with functional metastasis and need to be treated. This study aims to present a case of hyper-functional metastasis of thyroid cancer to analyze its pathological features, diagnostic procedures, and treatment options and to gather and examine recent cases of hyper-functional metastasis of thyroid cancer.</p><p><strong>Case presentation: </strong>A 26-year-old Iranian woman presenting with hyperthyroidism and a solid cystic nodule measuring 14.5 × 15.7 × 19.6 mm in the left thyroid lobe underwent thyroid surgery revealing papillary thyroid carcinoma. Despite lymph node metastasis, she refused further surgery and opted for lymph node radiofrequency ablation and radioactive iodine therapy. Subsequent follow-ups showed no recurrence of lymphadenopathy, normalized thyroid function, and decreasing triglyceride levels, with the patient under surveillance.</p><p><strong>Conclusion: </strong>Radioactive iodine is a first-line treatment option for patients with hyperactive thyroid cancer presenting with metastatic disease. Another therapeutic option is surgery, which is performed to maximize the reduction of thyroid tissue, lymph nodes, and distant metastasis.</p>","PeriodicalId":16236,"journal":{"name":"Journal of Medical Case Reports","volume":"18 1","pages":"537"},"PeriodicalIF":0.9000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558896/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13256-024-04820-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hyperthyroidism, caused by metastatic differentiated thyroid cancer, is a rare condition that can be difficult to diagnose. Thyrotoxicosis and metastatic disease regarding functional metastasis increase morbidity and mortality in patients with functional metastasis and need to be treated. This study aims to present a case of hyper-functional metastasis of thyroid cancer to analyze its pathological features, diagnostic procedures, and treatment options and to gather and examine recent cases of hyper-functional metastasis of thyroid cancer.
Case presentation: A 26-year-old Iranian woman presenting with hyperthyroidism and a solid cystic nodule measuring 14.5 × 15.7 × 19.6 mm in the left thyroid lobe underwent thyroid surgery revealing papillary thyroid carcinoma. Despite lymph node metastasis, she refused further surgery and opted for lymph node radiofrequency ablation and radioactive iodine therapy. Subsequent follow-ups showed no recurrence of lymphadenopathy, normalized thyroid function, and decreasing triglyceride levels, with the patient under surveillance.
Conclusion: Radioactive iodine is a first-line treatment option for patients with hyperactive thyroid cancer presenting with metastatic disease. Another therapeutic option is surgery, which is performed to maximize the reduction of thyroid tissue, lymph nodes, and distant metastasis.
期刊介绍:
JMCR is an open access, peer-reviewed online journal that will consider any original case report that expands the field of general medical knowledge. Reports should show one of the following: 1. Unreported or unusual side effects or adverse interactions involving medications 2. Unexpected or unusual presentations of a disease 3. New associations or variations in disease processes 4. Presentations, diagnoses and/or management of new and emerging diseases 5. An unexpected association between diseases or symptoms 6. An unexpected event in the course of observing or treating a patient 7. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect